Acute Lymphoblastic Leukemia

Oncology of Infancy and Childhood: Expert Consult - Online and Print

Volumn , Issue , 2009, Pages 295-330

  Silverman, Lewis B ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85158998850     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3431-5.00010-8     Document Type: Chapter

References (495)

1. LAG Ries, MA Smith, JG Gurney, et al. (1999) Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute, SEER Program (Publication No. 99-4649)
2. A Moghrabi, DE Levy, B Asselin, et al. (2007) Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109 896-904
3. A Moricke, A Reiter, M Zimmermann, et al. (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111 4477-4489
4. CH Pui, JT Sandlund, D Pei, et al. (2004) Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital. Blood 104 2690-2696
5. R Invernizzi, C Rosanda, G Basso, et al. (1992) Granular acute lymphoblastic leukemia in children. “Aieop Cooperative Group for Cytology of Acute Leukemias.”. Haematologica 77 30-34
6. JM Bennett, D Catovsky, MT Daniel, et al. (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33 451-458
7. CH Pui (1995) Childhood leukemias. N Engl J Med. 332 1618-1630
8. D Hammond, H Sather, M Nesbit, et al. (1986) Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 14 124-134
9. J van Eys, J Pullen, D Head, et al. (1986) The French-American-British (FAB) classification of leukemia. The Pediatric Oncology Group experience with lymphocytic leukemia. Cancer 57 1046-1051
10. JS Lilleyman, IM Hann, RF Stevens, et al. (1992) Cytomorphology of childhood lymphoblastic leukaemia: a prospective study of 2000 patients. United Kingdom Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol 81 52-57
11. C Patte, A Auperin, J Michon, et al. (2001) The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97 3370-3379
12. MS Cairo, M Gerrard, R Sposto, et al. (2007) Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109 2736-2743
13. JS Lilleyman, JA Britton, LM Anderson, et al. (1994) Periodic acid Schiff reaction in childhood lymphoblastic leukaemia. The Medical Research Council Working Party on Childhood Leukaemia. J Clin Pathol 47 689-692
14. R McCaffrey, TA Harrison, R Parkman and D Baltimore (1975) Terminal deoxynucleotidyl transferase activity in human leukemic cells and in normal human thymocytes. N Engl J Med 292 775-780
15. JJ Hutton and MS Coleman (1976) Terminal deoxynucleotidyl transferase measurements in the differential diagnosis of adult leukaemias. Br J Haematol 34 447-456
16. LB Vogler, WM Crist, DE Bockman, et al. (1978) Pre-B-cell leukemia. A new phenotype of childhood lymphoblastic leukemia. N Engl J Med 298 872-878
17. LM Nadler, SJ Korsmeyer, KC Anderson, et al. (1984) B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest 74 332-340
18. MF Greaves (1986) Differentiation-linked leukemogenesis in lymphocytes. Science 234 697-704
19. A Rolink and F Melchers (1991) Molecular and cellular origins of B lymphocyte diversity. Cell 66 1081-1094
20. CH Pui, FG Behm and WM Crist (1993) Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82 343-362
21. WM Crist, CE Grossi, DJ Pullen, et al. (1985) Immunologic markers in childhood acute lymphocytic leukemia. Semin Oncol 12 105-121
22. DJ Pullen, JM Boyett, WM Crist, et al. (1984) Pediatric oncology group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response. Ann N Y Acad Sci 428 26-48
23. CA Felix, DG Poplack, GH Reaman, et al. (1990) Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol 8 431-442
24. SJ Korsmeyer, PA Hieter, JV Ravetch, et al. (1981) Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. Proc Natl Acad Sci U S A 78 7096-7100
25. CA Hurwitz, MR Loken, ML Graham, et al. (1988) Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood 72 299-307
26. IM Hann, SM Richards, OB Eden, et al. (1998) Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party. Leukemia 12 1249-1255
27. B Stark, R Vogel, IJ Cohen, et al. (1989) Biologic and cytogenetic characteristics of leukemia in infants. Cancer 63 117-125
28. CS Chen, PH Sorensen, PH Domer, et al. (1993) Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 81 2386-2393
29. CH Pui, FG Behm, JR Downing, et al. (1994) 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 12 909-915
30. MC Bene, G Castoldi, W Knapp, et al. (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9 1783-1786
31. AJ Carroll, WM Crist, RT Parmley, et al. (1984) Pre-B cell leukemia associated with chromosome translocation 1;19. Blood 63 721-724
32. W Crist, J Boyett, M Roper, et al. (1984) Pre-B cell leukemia responds poorly to treatment: a pediatric oncology group study. Blood 63 407-414
33. WM Crist, AJ Carroll, JJ Shuster, et al. (1990) Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 76 117-122
34. SC Raimondi, FG Behm, PK Roberson, et al. (1990) Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 8 1380-1388
35. FM Uckun, MG Sensel, HN Sather, et al. (1998) Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 16 527-535
36. MP Sullivan, DJ Pullen, WM Crist, et al. (1990) Clinical and biological heterogeneity of childhood B cell acute lymphocytic leukemia: implications for clinical trials. Leukemia 4 6-11
37. R Berger and A Bernheim (1982) Cytogenetic studies on Burkitt's lymphoma-leukemia. Cancer Genet Cytogenet 7 231-244
38. CM Croce (1986) Chromosome translocations and human cancer. Cancer Res 46 6019-6023
39. JM Goldberg, LB Silverman, DE Levy, et al. (2003) Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 21 3616-3622
40. SE Sallan, J Ritz, J Pesando, et al. (1980) Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood 55 395-402
41. LB Silverman, L Declerck, RD Gelber, et al. (2000) Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 14 2247-2256
42. M Roper, WM Crist, R Metzgar, et al. (1983) Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies. Blood 61 830-837
43. WM Crist, JJ Shuster, J Falletta, et al. (1988) Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. Blood 72 1891-1897
44. JJ Shuster, JM Falletta, DJ Pullen, et al. (1990) Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 75 166-173
45. FM Uckun, PS Gaynon, MG Sensel, et al. (1997) Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol 15 2214-2221
46. LJ Smith, JE Curtis, HA Messner, et al. (1983) Lineage infidelity in acute leukemia. Blood 61 1138-1145
47. FM Uckun, A Muraguchi, JA Ledbetter, et al. (1989) Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 73 1000-1015
48. CH Pui, FG Behm, B Singh, et al. (1990) Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 75 198-202
49. FM Uckun, HN Sather, PS Gaynon, et al. (1997) Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 90 28-35
50. WD Ludwig, CR Bartram, J Harbott, et al. (1989) Phenotypic and genotypic heterogeneity in infant acute leukemia. I. Acute lymphoblastic leukemia. Leukemia 3 431-439
51. C Hirsch-Ginsberg, C Childs, KS Chang, et al. (1988) Phenotypic and molecular heterogeneity in Philadelphia chromosome-positive acute leukemia. Blood 71 186-195
52. CH Pui, LS Frankel, AJ Carroll, et al. (1991) Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood 77 440-447
53. CH Pui, JE Rubnitz, ML Hancock, et al. (1998) Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol 16 3768-3773
54. SR Wiersma, J Ortega, E Sobel and KI Weinberg (1991) Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 324 800-808
55. AS Dubansky, JM Boyett, J Falletta, et al. (1989) Isolated thrombocytopenia in children with acute lymphoblastic leukemia: a rare event in a Pediatric Oncology Group Study. Pediatrics 84 1068-1071
56. M Smith, D Arthur, B Camitta, et al. (1996) Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14 18-24
57. RP Nelken and JA Stockman 3rd (1976) The hypereosinophilic syndrome in association with acute lymphoblastic leukemia. J Pediatr 89 771-773
58. RS Wimmer, RB Raney Jr and JL Naiman (1978) Hypereosinophilia with acute lymphocytic and acute myelocytic leukemia in childhood. J Pediatr 92 244-246
59. JC Grimaldi and TC Meeker (1989) The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood 73 2081-2085
60. TF Hogan, W Koss, AJ Murgo, et al. (1987) Acute lymphoblastic leukemia with chromosomal 5;14 translocation and hypereosinophilia: case report and literature review. J Clin Oncol 5 382-390
61. MA Lichtman, J Heal and JM Rowe (1987) Hyperleukocytic leukaemia: rheological and clinical features and management. Baillieres Clin Haematol 1 725-746
62. NJ Bunin and CH Pui (1985) Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 3 1590-1595
63. EJ Lowe, CH Pui, ML Hancock, et al. (2005) Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer 45 10-15
64. IM Hann, DI Evans, HB Marsden, et al. (1978) Bone marrow fibrosis in acute lymphoblastic leukaemia of childhood. J Clin Pathol 31 313-315
65. JM Eguiguren and CH Pui (1992) Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 20 58-60
66. RB Raney and CW McMillan (1969) Simultaneous disparity of bone marrow specimens in acute leukemia. Am J Dis Child 117 548-552
67. AH Ragab and WM Crist (1972) Morphologic discordance in acute leukemia. N Engl J Med 287 1134-1135
68. EA Raetz, SL Perkins, D Bhojwani, et al. (2006) Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 47 130-140
69. A Reiter, M Schrappe, WD Ludwig, et al. (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95 416-421
70. O Neth, K Seidemann, P Jansen, et al. (2000) Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol 35 20-27
71. HH Mahmoud, GK Rivera, ML Hancock, et al. (1993) Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 329 314-319
72. B Burger, M Zimmermann, G Mann, et al. (2003) Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 21 184-188
73. S McIntosh and AK Ritchey (1986) Diagnostic problems in cerebrospinal fluid of children with lymphoid malignancies. Am J Pediatr Hematol Oncol 8 28-31
74. A Gajjar, PL Harrison, JT Sandlund, et al. (2000) Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 96 3381-3384
75. LC Ingram, DL Fairclough, WL Furman, et al. (1991) Cranial nerve palsy in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Cancer 67 2262-2268
76. S Krishnamurthy, AL Weinstock, SH Smith, et al. (2002) Facial palsy, an unusual presenting feature of childhood leukemia. Pediatr Neurol 27 68-70
77. DE Greydanus, EO Burgert Jr and GS Gilchrist (1978) Hypothalamic syndrome in children with acute lymphocytic leukemia. Mayo Clin Proc 53 217-220
78. NP Rosman, BA Kakulas and EP Richardson Jr (1966) Central pontine myelinolysis in a child with leukemia. Arch Neurol 14 273-280
79. SP Kanner, PH Wiernik, AA Serpick, et al. (1970) CNS leukemia mimicking multifocal leukoencephalopathy. Am J Dis Child 119 264-266
80. VI Miller and WG Campbell Jr (1971) Diabetes insipidus as a complication of leukemia. A case report with a literature reviews. Cancer 28 666-673
81. A Kataoka, K Shimizu, T Matsumoto, et al. (1995) Epidural spinal cord compression as an initial symptom in childhood acute lymphoblastic leukemia: rapid decompression by local irradiation and systemic chemotherapy. Pediatr Hematol Oncol 12 179-184
82. N Hijiya, W Liu, JT Sandlund, et al. (2005) Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation. Leukemia 19 1399-1403
83. N Sirvent, S Suciu, Y Bertrand, et al. (2007) Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: results of the EORTC CLG study 58881. Pediatr Blood Cancer 49 344-348
84. TH Kim, HK Hargreaves, WC Chan, et al. (1986) Sequential testicular biopsies in childhood acute lymphocytic leukemia. Cancer 57 1038-1041
85. TS Goh, GW LeQuesne and KY Wong (1978) Severe infiltration of the kidneys with ultrasonic abnormalities in acute lymphoblastic leukemia. Am J Dis Child 132 1204-1205
86. SC Howard, SD Kaplan, BI Razzouk, et al. (2003) Urolithiasis in pediatric patients with acute lymphoblastic leukemia. Leukemia 17 541-546
87. CW Troup, G Thatcher and NB Hodgson (1972) Infiltrative lesion of the bladder presenting as gross hematuria in child with leukemia: case report. J Urol 107 314-315
88. M Castagnetti, L Sainati, F Giona, et al. (2008) Conservative management of priapism secondary to leukemia. Pediatr Blood Cancer 51 420-423
89. HO Hustu and RJ Aur (1978) Extramedullary leukaemia. Clin Haematol 7 313-337
90. AJ Cecalupo, LS Frankel and MP Sullivan (1982) Pelvic and ovarian extramedullary leukemic relapse in young girls: a report of four cases and review of the literature. Cancer 50 587-593
91. SO Zarrouk, TH Kim, HK Hargreaves, et al. (1982) Leukemic involvement of the ovaries in childhood acute lymphocytic leukemia. J Pediatr 100 422-424
92. OG Jonsson, P Sartain, JM Ducore, et al. (1990) Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with almost normal hematologic indexes. J Pediatr 117 233-237
93. RJ Rogalsky, GB Black and MH Reed (1986) Orthopaedic manifestations of leukemia in children. J Bone Joint Surg Am 68 494-501
94. JM Halton, SA Atkinson, L Fraher, et al. (1995) Mineral homeostasis and bone mass at diagnosis in children with acute lymphoblastic leukemia. J Pediatr 126 557-564
95. FT Saulsbury and H Sabio (1985) Acute leukemia presenting as arthritis in children. Clin Pediatr (Phila) 24 625-628
96. OY Jones, CH Spencer, SL Bowyer, et al. (2006) A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis. Pediatrics 117 e840-844
97. RC Ribeiro, CH Pui and MJ Schell (1988) Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children. Cancer 61 589-592
98. DC Kushner, HJ Weinstein and JA Kirkpatrick (1980) The radiologic diagnosis of leukemia and lymphoma in children. Semin Roentgenol 15 316-334
99. RG Hughes and HE Kay (1982) Major bone lesions in acute lymphoblastic leukaemia. Med Pediatr Oncol 10 67-70
100. AF Belgaumi and MM Hudson (2001) Childhood acute lymphoblastic leukemia presenting with severe hepatic dysfunction. Med Pediatr Oncol 37 142-144
101. JF Kelleher, PM Monteleone, DA Steele, et al. (2001) Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 23 117-121
102. AP Schachat, JA Markowitz, DR Guyer, et al. (1989) Ophthalmic manifestations of leukemia. Arch Ophthalmol 107 697-700
103. DR Guyer, AP Schachat, S Vitale, et al. (1989) Leukemic retinopathy. Relationship between fundus lesions and hematologic parameters at diagnosis. Ophthalmology 96 860-864
104. CL Schwartz, NR Miller, MD Wharam, et al. (1989) The optic nerve as the site of initial relapse in childhood acute lymphoblastic leukemia. Cancer 63 1616-1620
105. N Bunin, G Rivera, F Goode, et al. (1987) Ocular relapse in the anterior chamber in childhood acute lymphoblastic leukemia. J Clin Oncol 5 299-303
106. D Bresters, AC Reus, AJ Veerman, et al. (2002) Congenital leukaemia: the Dutch experience and review of the literature. Br J Haematol 117 513-524
107. SJ Jubelirer and R Harpold (2002) The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. Clin Appl Thromb Hemost 8 73-76
108. GD Shackelford, G Bloomberg and WH McAlister (1972) The value of roentgenography in differentiating aplastic anemia from leukemia masquerading as aplastic anemia. Am J Roentgenol Radium Ther Nucl Med 116 651-654
109. H Hasle, S Heim, H Schroeder, et al. (1995) Transient pancytopenia preceding acute lymphoblastic leukemia (pre-ALL). Leukemia 9 605-608
110. YH Matloub, RD Brunning, DC Arthur, et al. (1993) Severe aplastic anemia preceding acute lymphoblastic leukemia. Cancer 71 264-268
111. A Moricke, M Zimmermann, A Reiter, et al. (2005) Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr 217 310-320
112. CH Pui, PS Gaynon, JM Boyett, et al. (2002) Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359 1909-1915
113. JM Chessells, CJ Harrison, SL Watson, et al. (2002) Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol 117 306-314
114. JM Hilden, PA Dinndorf, SO Meerbaum, et al. (2006) Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 108 441-451
115. R Pieters, M Schrappe, P De Lorenzo, et al. (2007) A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370 240-250
116. E Barry, DJ DeAngelo, D Neuberg, et al. (2007) Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 25 813-819
117. A Baruchel, JM Cayuela, P Ballerini, et al. (1997) Most myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. Br J Haematol 99 101-106
118. F Carbonell, J Swansbury, T Min, et al. (1996) Cytogenetic findings in acute biphenotypic leukaemia. Leukemia 10 1283-1287
119. MC Putti, R Rondelli, MG Cocito, et al. (1998) Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 92 795-801
120. AT Look, PK Roberson, DL Williams, et al. (1985) Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 65 1079-1086
121. R Trueworthy, J Shuster, T Look, et al. (1992) Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 10 606-613
122. ML Loh, MA Goldwasser, LB Silverman, et al. (2006) Prospective analysis of TEL/AML1 positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 107 4508-4513
123. JE Rubnitz, D Wichlan, M Devidas, et al. (2008) Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 26 2186-2191
124. AV Moorman, SM Richards, HM Robinson, et al. (2007) Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109 2327-2330
125. MB Harris, JJ Shuster, A Carroll, et al. (1992) Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 79 3316-3324
126. NA Heerema, HN Sather, MG Sensel, et al. (2000) Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (>50 chromosomes). J Clin Oncol 18 1876-1887
127. MJ Sutcliffe, JJ Shuster, HN Sather, et al. (2005) High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. Leukemia 19 734-740
128. CJ Harrison, AV Moorman, KE Barber, et al. (2005) Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol 129 520-530
129. E Forestier and K Schmiegelow (2006) The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol 28 486-495
130. A Attarbaschi, G Mann, M Konig, et al. (2004) Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis. Leukemia 18 1611-1616
131. E Forestier, MK Andersen, K Autio, et al. (2007) Cytogenetic patterns in ETV6/RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia: a Nordic series of 245 cases and review of the literature. Genes Chromosomes Cancer 46 440-450
132. TW McLean, S Ringold, D Neuberg, et al. (1996) TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 88 4252-4258
133. JE Rubnitz, JR Downing, CH Pui, et al. (1997) TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 15 1150-1157
134. J Harbott, S Viehmann, A Borkhardt, et al. (1997) Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 90 4933-4937
135. K Seeger, HP Adams, D Buchwald, et al. (1998) TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood 91 1716-1722
136. ML Loh, LB Silverman, ML Young, et al. (1998) Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 92 4792-4797
137. K Seeger, A von Stackelberg, T Taube, et al. (2001) Relapse of TEL-AML1—positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J Clin Oncol 19 3188-3193
138. JM Chessels, GJ Swansbury, B Reeves, et al. (1997) Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 99 93-100
139. NA Heerema, JB Nachman, HN Sather, et al. (1999) Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group. Blood 94 4036-4045
140. JB Nachman, NA Heerema, H Sather, et al. (2007) Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110 1112-1115
141. FG Behm, SC Raimondi, JL Frestedt, et al. (1996) Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 87 2870-2877
142. W Crist, A Carroll, J Shuster, et al. (1990) Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood 76 489-494
143. JA Fletcher, EA Lynch, VM Kimball, M Donnelly, R Tantravahi and SE Sallan (1991) Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 77 435-439
144. FM Uckun, JB Nachman, HN Sather, et al. (1998) Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer 83 2030-2039
145. M Arico, MG Valsecchi, B Camitta, et al. (2000) Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342 998-1006
146. CH Pui, HH Mahmoud, GK Rivera, et al. (1998) Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 92 411-415
147. PS Gaynon, AA Desai, BC Bostrom, et al. (1997) Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 80 1717-1726
148. LB Silverman, RD Gelber, ML Young, et al. (1999) Induction failure in acute lymphoblastic leukemia of childhood. Cancer 85 1395-1404
149. C Oudot, MF Auclerc, V Levy, et al. (2008) Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 26 1496-1503
150. M Schrappe, A Reiter, M Zimmermann, et al. (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14 2205-2222
151. J Rautonen, L Hovi and MA Siimes (1988) Slow disappearance of peripheral blast cells: an independent risk factor indicating poor prognosis in children with acute lymphoblastic leukemia. Blood 71 989-991
152. A Gajjar, R Ribeiro, ML Hancock, et al. (1995) Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 86 1292-1295
153. TC Griffin, JJ Shuster, GR Buchanan, et al. (2000) Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 14 792-795
154. JB Nachman, HN Sather, MG Sensel, et al. (1998) Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338 1663-1671
155. JJ van Dongen, T Seriu, ER Panzer-Grumayer, et al. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352 1731-1738
156. E Coustan-Smith, FG Behm, J Sanchez, et al. (1998) Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 351 550-554
157. EG Weir, K Cowan, P LeBeau, et al. (1999) A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 13 558-567
158. A Li, J Zhou, D Zuckerman, et al. (2003) Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood 102 4520-4526
159. H Cave, J van der Werff ten Bosch, S Suciu, et al. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer—Childhood Leukemia Cooperative Group. N Engl J Med 339 591-598
160. E Coustan-Smith, J Sancho, ML Hancock, et al. (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96 2691-2696
161. C Nyvold, HO Madsen, LP Ryder, et al. (2002) Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 99 1253-1258
162. ER Panzer-Grümayer, M Schneider, et al. (2000) Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 95 790-794
163. J Zhou, MA Goldwasser, A Li, et al. (2007) Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 110 1607-1611
164. MJ Brisco, J Condon, E Hughes, et al. (1994) Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343 196-200
165. E Coustan-Smith, J Sancho, FG Behm, et al. (2002) Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 100 52-58
166. JM Chessells, SM Richards, CC Bailey, et al. (1995) Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol 89 364-372
167. JJ Shuster, P Wacker, J Pullen, et al. (1998) Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 16 2854-2863
168. CH Pui, JM Boyett, ML Hancock, et al. (1995) Outcome of treatment for childhood cancer in black as compared with white children. The St Jude Children's Research Hospital experience, 1962 through 1992. JAMA 273 633-637
169. BH Pollock, MR DeBaun, BM Camitta, et al. (2000) Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 18 813-823
170. L Kager and WE Evans (2006) Pharmacogenomics of acute lymphoblastic leukemia. Curr Opin Hematol 13 260-265
171. MV Relling, ML Hancock, JM Boyett, et al. (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93 2817-2823
172. M Stanulla, E Schaeffeler, T Flohr, et al. (2005) Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293 1485-1489
173. MV Relling, ML Hancock, GK Rivera, et al. (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91 2001-2008
174. MV Relling, JE Rubnitz, GK Rivera, et al. (1999) High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354 34-39
175. M Stanulla, M Schrappe, AM Brechlin, et al. (2000) Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 95 1222-1228
176. SM Davies, S Bhatia, JA Ross, et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100 67-71
177. M Krajinovic, I Costea and S Chiasson (2002) Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 359 1033-1034
178. M Krajinovic, E Lemieux-Blanchard, S Chiasson, et al. (2004) Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 4 66-72
179. M Lauten, G Asgedom, K Welte, et al. (2003) Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica 88 353-354
180. S Farber, LK Diamond, RD Mercer, et al. (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 238 787-793
181. E Frei 3rd (1984) Acute leukemia in children. Model for the development of scientific methodology for clinical therapeutic research in cancer. Cancer 53 2013-2025
182. GB Elion and GH Hitchings (1965) Metabolic basis for the actions of analogs of purines and pyrimidines. Adv Chemother 2 91-177
183. JH Burchenal, ML Murphy, RR Ellison, et al. (1953) Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 8 965-999
184. E Frei 3rd, JF Holland, MA Schneiderman, et al. (1958) A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 13 1126-1148
185. EJ Freireich and E Frei 2nd (1964) Recent advances in acute leukemia. Prog Hematol 4 187-202
186. RH Blum and SK Carter (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80 249-259
187. L Tallal, C Tan, H Oettgen, et al. (1970) E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 25 306-320
188. N Jaffe, D Traggis, L Das, et al. (1972) Comparison of daily and twice-weekly schedule of L-asparaginase in childhood leukemia. Pediatrics 49 590-595
189. KR Schultz, DJ Pullen, HN Sather, et al. (2007) Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 109 926-935
190. JF Holland and O Glidewell (1972) Chemotherapy of acute lymphocytic leukemia of childhood. Cancer 30 1480-1487
191. DH Berry, J Pullen, S George, et al. (1975) Comparison of prednisolone, vincristine, methotrexate, and 6-mercaptopurine vs. vincristine and prednisone induction therapy in childhood acute leukemia. Cancer 36 98-102
192. JA Ortega, ME Nesbit Jr, MH Donaldson, et al. (1977) L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res 37 535-540
193. S Hitchcock-Bryan, R Gelber, JR Cassady and SE Sallan (1986) The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 14 211-215
194. JH Goldie, AJ Coldman and GA Gudauskas (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66 439-449
195. PS Gaynon, PG Steinherz, WA Bleyer, et al. (1993) Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Children's Cancer Group Study CCG-106. J Clin Oncol 11 2234-2242
196. DG Tubergen, GS Gilchrist, RT O’Brien, et al. (1993) Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol 11 527-537
197. CH Pui, JM Boyett, GK Rivera, et al. (2000) Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 14 2286-2294
198. JE Rubnitz, S Lensing, Y Zhou, et al. (2004) Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer 101 1677-1684
199. J Ochs, GK Rivera, BH Pollock, et al. (1990) Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Cancer 66 1671-1677
200. F Giona, AM Testi, L Annino, et al. (1994) Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Associazione Italiana Ematologia ed Ocologia Pediatrica. Br J Haematol 86 55-61
201. G Rivera, GV Dahl, WP Bowman, et al. (1980) VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia. Cancer 46 1727-1730
202. SL Berg, SM Blaney, M Devidas, et al. (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 23 3376-3382
203. DJ DeAngelo, D Yu, JL Johnson, et al. (2007) Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109 5136-5142
204. A Balduzzi, MG Valsecchi, C Uderzo, et al. (2005) Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 366 635-642
205. D Pinkel, K Hernandez, L Borella, et al. (1971) Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 27 247-256
206. AE Evans, ES Gilbert and R Zandstra (1970) The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A.). Cancer 26 404-409
207. GK Rivera, D Pinkel, JV Simone, et al. (1993) Treatment of acute lymphoblastic leukemia. 30 years’ experience at St. Jude Children's Research Hospital. N Engl J Med 329 1289-1295
208. RE Johnson (1964) An experimental therapeutic approach to L1210 leukemia in mice: combined chemotherapy and central nervous system irradiation. J Natl Cancer Inst 32 1333-1341
209. HO Hustu, RJ Aur, MS Verzosa, et al. (1973) Prevention of central nervous system leukemia by irradiation. Cancer 32 585-597
210. J Simone, RJ Aur, HO Hustu, et al. (1972) “Total therapy” studies of acute lymphocytic leukemia in children. Current results and prospects for cure. Cancer 30 1488-1494
211. RJ Aur, JV Simone, HO Hustu, et al. (1972) A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia. Cancer 29 381-391
212. ME Nesbit, H Sather, LL Robison, et al. (1982) Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia: a Report from Children's Cancer Study Group. Cancer Res 42 674-680
213. CH Pui and SC Howard (2008) Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 9 257-268
214. ME Nesbit Jr, HN Sather, LL Robison, et al. (1981) Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukaemia: comparison of 1800 rad and 2400 rad. A report for Children's Cancer Study Group. Lancet 1 461-466
215. M Schrappe, A Reiter, G Henze, et al. (1998) Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Klin Padiatr 210 192-199
216. FM Balis, CM Lester, GP Chrousos, et al. (1987) Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5 202-207
217. J Frick, PS Ritch, RM Hansen, et al. (1984) Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 2 365-368
218. JJ Wang, AI Freeman and LF Sinks (1976) Treatment of acute lymphocytic leukemia by high-dose intravenous methotrexate. Cancer Res 36 1441-1444
219. SP Dibenedetto, A Di Cataldo, R Ragusa, et al. (1995) Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. J Clin Oncol 13 339-344
220. MH Woo, LJ Hak, MC Storm, et al. (1999) Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 17 1568-1573
221. DG Tubergen, GS Gilchrist, RT O’Brien, et al. (1993) Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. J Clin Oncol 11 520-526
222. JM LeClerc, AL Billett, RD Gelber, et al. (2002) Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol 20 237-246
223. BC Bostrom, MR Sensel, HN Sather, et al. (2003) Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 101 3809-3817
224. CD Mitchell, SM Richards, SE Kinsey, et al. (2005) Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129 734-745
225. J Pullen, J Boyett, J Shuster, et al. (1993) Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 11 839-849
226. V Conter, M Arico, MG Valsecchi, et al. (1995) Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. J Clin Oncol 13 2497-2502
227. AJ Veerman, K Hahlen, WA Kamps, et al. (1996) High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14 911-918
228. FG Hill, S Richards, B Gibson, et al. (2004) Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 124 33-46
229. DH Mahoney Jr, JJ Shuster, R Nitschke, et al. (1998) Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy—a Pediatric Oncology Group study. J Clin Oncol 16 1712-1722
230. SE Sallan, S Hitchcock-Bryan, R Gelber, et al. (1983) Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 43 5601-5607
231. M Schrappe, A Reiter, WD Ludwig, et al. (2000) Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95 3310-3322
232. WA Kamps, AJ Veerman, ER van Wering, et al. (2000) Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia 14 2240-2246
233. G Gustafsson, K Schmiegelow, E Forestier, et al. (2000) Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 14 2267-2275
234. AR Chauvenet, PL Martin, M Devidas, et al. (2007) Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood 110 1105-1111
235. PS Gaynon, ME Trigg, NA Heerema, et al. (2000) Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 14 2223-2233
236. M Arico, MG Valsecchi, V Conter, et al. (2002) Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 100 420-426
237. BJ Lange, BC Bostrom, JM Cherlow, et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99 825-833
238. NL Seibel, PG Steinherz, HN Sather, et al. (2008) Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 111 2548-2555
239. WA Bleyer, HN Sather, HJ Nickerson, et al. (1991) Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol 9 1012-1021
240. Childhood ALL Collaborative Group (1996) Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12,000 randomised children. Lancet 347 1783-1788
241. V Conter, MG Valsecchi, D Silvestri, et al. (2007) Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 369 123-131
242. FM Balis, JL Savitch and WA Bleyer (1983) Pharmacokinetics of oral methotrexate in children. Cancer Res 43 2342-2345
243. L Lennard and JS Lilleyman (1989) Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7 1816-1823
244. DG Poplack, FM Balis and S Zimm (1986) The pharmacology of orally administered chemotherapy. A reappraisal. Cancer 58 473-480
245. R Riccardi, FM Balis, P Ferrara, et al. (1986) Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 3 319-324
246. K Schmiegelow, H Schroder, G Gustafsson, et al. (1995) Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 13 345-351
247. G Koren, G Ferrazini, H Sulh, et al. (1990) Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 323 17-21
248. GE Rivard, C Infante-Rivard, C Hoyoux, et al. (1985) Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening. Lancet 2 1264-1266
249. K Schmiegelow, A Glomstein, J Kristinsson, et al. (1997) Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). J Pediatr Hematol Oncol 19 102-109
250. K Schmiegelow and MK Pulczynska (1990) Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts? Am J Pediatr Hematol Oncol 12 462-467
251. AD Pearson, HA Amineddine, M Yule, et al. (1991) The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia. Br J Cancer 64 169-173
252. RC Lau, D Matsui, M Greenberg and G Koren (1998) Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. Med Pediatr Oncol 30 85-90
253. M Peeters, G Koren, D Jakubovicz, et al. (1988) Physician compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther 43 228-232
254. N Erb, DO Harms and G Janka-Schaub (1998) Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 42 266-272
255. PC Adamson, DG Poplack and FM Balis (1994) The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res 18 805-810
256. A Vora, CD Mitchell, L Lennard, et al. (2006) Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 368 1339-1348
257. SS Jacobs, LC Stork, BC Bostrom, et al. (2007) Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). Pediatr Blood Cancer 49 250-255
258. B Jones, AI Freeman, JJ Shuster, et al. (1991) Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19 269-275
259. C Ito, WE Evans, L McNinch, et al. (1996) Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 14 2370-2376
260. GJ Kaspers, AJ Veerman, C Popp-Snijders, et al. (1996) Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 27 114-121
261. LB Silverman, RD Gelber, VK Dalton, et al. (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97 1211-1218
262. AJ Strauss, JT Su, VM Dalton, et al. (2001) Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol 19 3066-3072
263. CA Hurwitz, LB Silverman, MA Schorin, et al. (2000) Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 88 1964-1969
264. GK Rivera, SC Raimondi, ML Hancock, et al. (1991) Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337 61-66
265. CH Pui, RC Ribeiro, ML Hancock, et al. (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325 1682-1687
266. JV Simone, RJ Aur, HO Hustu, et al. (1978) Three to ten years after cessation of therapy in children with leukemia. Cancer 42 839-844
267. ME Nesbit Jr, HN Sather, LL Robison, et al. (1983) Randomized study of 3 years versus 5 years of chemotherapy in childhood acute lymphoblastic leukemia. J Clin Oncol 1 308-316
268. DR Miller, SL Leikin, VC Albo, et al. (1989) Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol 7 316-325
269. OB Eden, JS Lilleyman, S Richards, et al. (1991) Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol 78 187-196
270. Y Ravindranath, DT Soorya, GE Schultz and JM Lusher (1981) Long-term survivors of acute lymphoblastic leukemia—risk of relapse after cessation of therapy. Med Pediatr Oncol 9 209-218
271. Y Toyoda, A Manabe, M Tsuchida, et al. (2000) Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18 1508-1516
272. CD Bloomfield, AI Goldman, G Alimena, et al. (1986) Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 67 415-420
273. AJ Barrett, MM Horowitz, RC Ash, et al. (1992) Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 79 3067-3070
274. J Sierra, J Radich, JA Hansen, et al. (1997) Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 90 1410-1414
275. DI Marks, JM Bird, JM Cornish, et al. (1998) Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia. J Clin Oncol 16 931-936
276. OG Ottmann, BJ Druker, CL Sawyers, et al. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 1965-1971
277. MA Champagne, R Capdeville, M Krailo, et al. (2004) Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 104 2655-2660
278. DA Thomas, S Faderl, J Cortes, et al. (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 4396-4407
279. A de Labarthe, P Rousselot, F Huguet-Rigal, et al. (2007) Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109 1408-1413
280. A Biondi, G Cimino, R Pieters and CH Pui (2000) Biological and therapeutic aspects of infant leukemia. Blood 96 24-33
281. JM Chessells, OB Eden, CC Bailey, et al. (1994) Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 8 1275-1279
282. GH Reaman, R Sposto, MG Sensel, et al. (1999) Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 17 445-455
283. A Biondi, C Rizzari, MG Valsecchi, et al. (2006) Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. Haematologica 91 534-537
284. LS Frankel, J Ochs, JJ Shuster, et al. (1997) Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 19 35-42
285. M Dordelmann, A Reiter, A Borkhardt, et al. (1999) Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 94 1209-1217
286. K Isoyama, M Eguchi, S Hibi, et al. (2002) Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol 118 999-1010
287. R Pieters, ML den Boer, M Durian, et al. (1998) Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia—implications for treatment of infants. Leukemia 12 1344-1348
288. LB Silverman, TW McLean, RD Gelber, et al. (1997) Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer 80 2285-2295
289. NL Ramakers-van Woerden, HB Beverloo, AJ Veerman, et al. (2004) In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 18 521-529
290. F Marco, E Bureo, JJ Ortega, et al. (2000) High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Espanol de Trasplante de Medula Osea en Ninos. J Clin Oncol 18 3256-3261
291. Y Kosaka, K Koh, N Kinukawa, et al. (2004) Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 104 3527-3534
292. JE Sanders, HJ Im, PA Hoffmeister, et al. (2005) Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 105 3749-3756
293. SA Armstrong, JE Staunton, LB Silverman, et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30 41-47
294. SA Armstrong, AL Kung, ME Mabon, et al. (2003) Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3 173-183
295. P Brown, M Levis, S Shurtleff, et al. (2005) FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 105 812-820
296. VM Santana, RK Dodge, WM Crist, et al. (1990) Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia. Leukemia 4 87-90
297. LA Mattano Jr, HN Sather, ME Trigg, et al. (2000) Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 18 3262-3272
298. N Boissel, MF Auclerc, V Lheritier, et al. (2003) Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21 774-780
299. JM de Bont, B Holt, AW Dekker, et al. (2004) Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18 2032-2035
300. H Hallbook, G Gustafsson, B Smedmyr, et al. (2006) Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer 107 1551-1561
301. H Hasle, IH Clemmensen and M Mikkelsen (2000) Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355 165-169
302. B Zeller, G Gustafsson, E Forestier, et al. (2005) Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 128 797-804
303. JM Chessells, G Harrison, SM Richards, et al. (2001) Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 85 321-325
304. M Bassal, MK La, JA Whitlock, et al. (2005) Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 44 21-28
305. JA Whitlock, HN Sather, P Gaynon, et al. (2005) Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 106 4043-4049
306. J Blatt, V Albo, W Prin, et al. (1986) Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia. Lancet 2 914
307. MA Peeters, A Poon, A Zipursky, et al. (1986) Toxicity of leukaemia therapy in children with Down syndrome. Lancet 2 1279
308. MB Davidson, S Thakkar, JK Hix, et al. (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116 546-554
309. MS Cairo and M Bishop (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127 3-11
310. CH Pui, HH Mahmoud, JM Wiley, et al. (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19 697-704
311. SC Goldman, JS Holcenberg, JZ Finklestein, et al. (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97 2998-3003
312. T Inukai, K Hirose, T Inaba, et al. (2007) Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia 21 288-296
313. P Rebulla, G Finazzi, F Marangoni, et al. (1997) The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med 337 1870-1875
314. RC Ribeiro and CH Pui (1986) The clinical and biological correlates of coagulopathy in children with acute leukemia. J Clin Oncol 4 1212-1218
315. SP Hunger (1996) Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 87 1211-1224
316. JR Priest, NK Ramsay, PG Steinherz, et al. (1982) A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 100 984-989
317. O Kucuk, HC Kwaan, W Gunnar, et al. (1985) Thromboembolic complications associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer 55 702-706
318. AC Homans, ME Rybak, RL Baglini, et al. (1987) Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol 5 811-817
319. AD Shapiro, SL Clarke, JM Christian, et al. (1993) Thrombosis in children receiving L-asparaginase. Determining patients at risk. Am J Pediatr Hematol Oncol 15 400-405
320. V Mall, KB Thomas, S Sauter, et al. (1999) Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Padiatr 211 205-210
321. U Nowak-Gottl, E Ahlke, G Fleischhack, et al. (2003) Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 101 2529-2533
322. PA Pizzo (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328 1323-1332
323. PA Pizzo and TJ Walsh (1990) Fungal infections in the pediatric cancer patient. Semin Oncol 17 6-9
324. SJ Chanock and PA Pizzo (1997) Infectious complications of patients undergoing therapy for acute leukemia: current status and future prospects. Semin Oncol 24 132-140
325. S Feldman, WT Hughes and CB Daniel (1975) Varicella in children with cancer: Seventy-seven cases. Pediatrics 56 388-397
326. R Winsnes (1978) Efficacy of zoster immunoglobulin in prophylaxis of varicella in high-risk patients. Acta Paediatr Scand 67 77-82
327. JA Zaia, MJ Levin, SR Preblud, et al. (1983) Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 147 737-743
328. HH Balfour Jr, B Bean, OL Laskin, et al. (1983) Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 308 1448-1453
329. G Hill, AR Chauvenet, J Lovato, et al. (2005) Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics 116 e525-e529
330. MM Gray, IM Hann, S Glass, et al. (1987) Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centres: a retrospective review. Br Med J (Clin Res Ed) 295 19-22
331. I Hughes, ME Jenney, RW Newton, et al. (1993) Measles encephalitis during immunosuppressive treatment for acute lymphoblastic leukaemia. Arch Dis Child 68 775-778
332. SE Siegel, ME Nesbit, R Baehner, et al. (1980) Pneumonia during therapy for childhood acute lymphoblastic leukemia. Am J Dis Child 134 28-34
333. WT Hughes, GK Rivera, MJ Schell, et al. (1987) Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 316 1627-1632
334. K Welte, A Reiter, K Mempel, et al. (1996) A randomized phase-III study of the efficacy of granulocyte colony- stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood 87 3143-3150
335. CH Pui, JM Boyett, WT Hughes, et al. (1997) Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336 1781-1787
336. OG Ottmann, D Hoelzer, E Gracien, et al. (1995) Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 86 444-450
337. K Geissler, E Koller, E Hubmann, et al. (1997) Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia—a randomized phase-III study. Blood 90 590-596
338. JA Katz, ML Wagner, MV Gresik, et al. (1990) Typhlitis. An 18-year experience and postmortem review. Cancer 65 1041-1047
339. MB McCarville, CS Adelman, C Li, et al. (2005) Typhlitis in childhood cancer. Cancer 104 380-387
340. AE Ojala, FP Lanning and BM Lanning (1997) Abdominal ultrasound findings during and after treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 29 266-271
341. JE Alexander, SL Williamson, JJ Seibert, et al. (1988) The ultrasonographic diagnosis of typhlitis (neutropenic colitis). Pediatr Radiol 18 200-204
342. MM Quigley, K Bethel, M Nowacki, et al. (2001) Neutropenic enterocolitis: a rare presenting complication of acute leukemia. Am J Hematol 66 213-219
343. AF Paulino, R Kenney, EN Forman, et al. (1994) Typhlitis in a patient with acute lymphoblastic leukemia prior to the administration of chemotherapy. Am J Pediatr Hematol Oncol 16 348-351
344. RC Shamberger, HJ Weinstein, MJ Delorey, et al. (1986) The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia. Cancer 57 603-609
345. CR Moir, CH Scudamore and WB Benny (1986) Typhlitis: selective surgical management. Am J Surg 151 563-566
346. JJ Ochs, WP Bowman, CH Pui, et al. (1984) Seizures in childhood lymphoblastic leukaemia patients. Lancet 2 1422-1424
347. NJ Winick, WP Bowman, BA Kamen, et al. (1992) Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 84 252-256
348. JE Freeman, PG Johnston and JM Voke (1973) Somnolence after prophylactic cranial irradiation in children with acute lymphoblastic leukaemia. BMJ 4 523-525
349. P Littman, J Rosenstock, G Gale, et al. (1984) The somnolence syndrome in leukemic children following reduced daily dose fractions of cranial radiation. Int J Radiat Oncol Biol Phys 10 1851-1853
350. LT Ch’ien, RJ Aur, S Stagner, et al. (1980) Long-term neurological implications of somnolence syndrome in children with acute lymphocytic leukemia. Ann Neurol 8 273-277
351. SS Legha (1986) Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1 421-427
352. MJ Stuart, C Cuaso, M Miller and FA Oski (1975) Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine. Blood 45 315-320
353. TJ Postma, BA Benard, PC Huijgens, et al. (1993) Long-term effects of vincristine on the peripheral nervous system. J Neurooncol 15 23-27
354. SK Parsons, SX Skapek, EJ Neufeld, et al. (1997) Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 89 1886-1895
355. CH Pui, GA Burghen, WP Bowman, et al. (1981) Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr 99 46-50
356. W Hogler, G Wehl, T van Staa, et al. (2007) Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database. Pediatr Blood Cancer 48 21-27
357. R Drigan, A Spirito and RD Gelber (1992) Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia. Med Pediatr Oncol 20 13-21
358. AT Meadows, J Gordon, DJ Massari, et al. (1981) Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukaemia treated with cranial irradiation. Lancet 2 1015-1018
359. JH Rowland, OJ Glidewell, RF Sibley, et al. (1984) Effects of different forms of central nervous system prophylaxis on neuropsychologic function in childhood leukemia. J Clin Oncol 2 1327-1335
360. M Jankovic, P Brouwers, MG Valsecchi, et al. (1994) Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet 344 224-227
361. DP Waber, G Gioia, J Paccia, et al. (1990) Sex differences in cognitive processing in children treated with CNS prophylaxis for acute lymphoblastic leukemia. J Pediatr Psychol 15 105-122
362. RW Butler, JM Hill, PG Steinherz, et al. (1994) Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol 12 2621-2629
363. DP Waber, BL Shapiro, SC Carpentieri, et al. (2001) Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer 92 15-22
364. DP Waber, NJ Tarbell, CM Kahn, et al. (1992) The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol 10 810-817
365. RK Mulhern, D Fairclough and J Ochs (1991) A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol 9 1348-1356
366. AH Harila-Saari, PM Lahteenmaki, E Pukkala, et al. (2007) Scholastic achievements of childhood leukemia patients: a nationwide, register-based study. J Clin Oncol 25 3518-3524
367. RK Mulhern, J Ochs, D Fairclough, et al. (1987) Intellectual and academic achievement status after CNS relapse: a retrospective analysis of 40 children treated for acute lymphoblastic leukemia. J Clin Oncol 5 933-940
368. K Longeway, R Mulhern, J Crisco, et al. (1990) Treatment of meningeal relapse in childhood acute lymphoblastic leukemia: II. A prospective study of intellectual loss specific to CNS relapse and therapy. Am J Pediatr Hematol Oncol 12 45-50
369. P Kumar, RK Mulhern, WF Regine, et al. (1995) A prospective neurocognitive evaluation of children treated with additional chemotherapy and craniospinal irradiation following isolated central nervous system relapse in acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 31 561-566
370. BJ Spiegler, K Kennedy, R Maze, et al. (2006) Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol 24 3858-3864
371. FE Halberg, JH Kramer, IM Moore, et al. (1992) Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 22 13-16
372. RK Mulhern, E Kovnar, J Langston, et al. (1992) Long-term survivors of leukemia treated in infancy: factors associated with neuropsychologic status. J Clin Oncol 10 1095-1102
373. DP Waber, J Turek, L Catania, et al. (2007) Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol 25 4914-4921
374. DR Copeland, BD Moore 3rd, DJ Francis, et al. (1996) Neuropsychologic effects of chemotherapy on children with cancer: a longitudinal study. J Clin Oncol 14 2826-2835
375. AI Buizer, LM de Sonneville, MM van den Heuvel-Eibrink, et al. (2006) Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor. Cancer 106 2067-2075
376. A Kingma, RI van Dommelen, EL Mooyaart, et al. (2001) Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr 139 413-420
377. DP Waber, NJ Tarbell, D Fairclough, et al. (1995) Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice. J Clin Oncol 13 2490-2496
378. CM Filley and BK Kleinschmidt-DeMasters (2001) Toxic leukoencephalopathy. N Engl J Med 345 425-432
379. RJ Aur, JV Simone, MS Verzosa, et al. (1978) Childhood acute lymphocytic leukemia: study VIII. Cancer 42 2123-2134
380. DP Waber, DK Urion, NJ Tarbell, et al. (1990) Late effects of central nervous system treatment of acute lymphoblastic leukemia in childhood are sex-dependent. Dev Med Child Neurol 32 238-248
381. T Humpl, K Bruhl, J Bohl, et al. (1997) Cerebral haemorrhage in long-term survivors of childhood acute lymphoblastic leukaemia. Eur J Pediatr 156 367-370
382. S Heckl, A Aschoff and S Kunze (2002) Radiation-induced cavernous hemangiomas of the brain: a late effect predominantly in children. Cancer 94 3285-3291
383. EA Schriock, MJ Schell, M Carter, et al. (1991) Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol 9 400-405
384. C Sklar, A Mertens, A Walter, et al. (1993) Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation. J Pediatr 123 59-64
385. E Didcock, HA Davies, M Didi, et al. (1995) Pubertal growth in young adult survivors of childhood leukemia. J Clin Oncol 13 2503-2507
386. VK Dalton, M Rue, LB Silverman, et al. (2003) Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol 21 2953-2960
387. EJ Chow, DL Friedman, Y Yasui, et al. (2007) Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr 150 370-375
388. JA Katz, B Chambers, C Everhart, et al. (1991) Linear growth in children with acute lymphoblastic leukemia treated without cranial irradiation. J Pediatr 118 575-578
389. ML Voorhess, ML Brecher, AS Glicksman, et al. (1986) Hypothalamic-pituitary function of children with acute lymphocytic leukemia after three forms of central nervous system prophylaxis. A retrospective study. Cancer 57 1287-1291
390. TG Stubberfield, GC Byrne and TW Jones (1995) Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. 18-Gy versus 24-Gy cranial irradiation. J Pediatr Hematol Oncol 17 167-171
391. PG Swift, PJ Kearney, RG Dalton, et al. (1978) Growth and hormonal status of children treated for acute lymphoblastic leukaemia. Arch Dis Child 53 890-894
392. I Odame, JJ Reilly, BE Gibson, et al. (1994) Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child 71 147-149
393. M Didi, E Didcock, HA Davies, et al. (1995) High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr 127 63-67
394. JE Van Dongen-Melman, AC Hokken-Koelega, K Hahlen, et al. (1995) Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res 38 86-90
395. KC Oeffinger, AC Mertens, CA Sklar, et al. (2003) Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 21 1359-1365
396. CA Sklar, AC Mertens, A Walter, et al. (2000) Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol 35 91-95
397. BI Razzouk, SR Rose, S Hongeng, et al. (2007) Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol 25 1183-1189
398. JM Halton, SA Atkinson, L Fraher, et al. (1996) Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 11 1774-1783
399. P Arikoski, J Komulainen, P Riikonen, et al. (1999) Reduced bone density at completion of chemotherapy for a malignancy. Arch Dis Child 80 143-148
400. IM van der Sluis, MM van den Heuvel-Eibrink, K Hahlen, et al. (2002) Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatr 141 204-210
401. P Arikoski, J Komulainen, R Voutilainen, et al. (1998) Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 20 234-240
402. N Kadan-Lottick, JA Marshall, AE Baron, et al. (2001) Normal bone mineral density after treatment for childhood acute lymphoblastic leukemia diagnosed between 1991 and 1998. J Pediatr 138 898-904
403. K Mandel, S Atkinson, RD Barr, et al. (2004) Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 22 1215-1221
404. SC Kaste, SN Rai, K Fleming, et al. (2006) Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 46 77-87
405. I Hanif, H Mahmoud and CH Pui (1993) Avascular femoral head necrosis in pediatric cancer patients. Med Pediatr Oncol 21 655-660
406. MJ Thornton, G O'Sullivan, MP Williams, et al. (1997) Avascular necrosis of bone following an intensified chemotherapy regimen including high dose steroids. Clin Radiol 52 607-612
407. SY Wei, AN Esmail, N Bunin, et al. (2000) Avascular necrosis in children with acute lymphoblastic leukemia. J Pediatr Orthop 20 331-335
408. B Burger, R Beier, M Zimmermann, et al. (2005) Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)—experiences from trial ALL-BFM 95. Pediatr Blood Cancer 44 220-225
409. SE Lipshultz, SD Colan, RD Gelber, et al. (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324 808-815
410. K Sorensen, G Levitt, C Bull, et al. (1997) Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol 15 61-68
411. SE Lipshultz, SR Lipsitz, SM Mone, et al. (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332 1738-1743
412. JP Krischer, S Epstein, DD Cuthbertson, et al. (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15 1544-1552
413. SE Lipshultz, N Rifai, VM Dalton, et al. (2004) Dexrazoxane reduces myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia: results from a randomized trial. N Engl J Med 351 145-153
414. C Quigley, C Cowell, M Jimenez, et al. (1989) Normal or early development of puberty despite gonadal damage in children treated for acute lymphoblastic leukemia. N Engl J Med 321 143-151
415. J Blatt, DG Poplack and RJ Sherins (1981) Testicular function in boys after chemotherapy for acute lymphoblastic leukemia. N Engl J Med 304 1121-1124
416. M Lendon, IM Hann, MK Palmer, et al. (1978) Testicular histology after combination chemotherapy in childhood for acute lymphoblastic leukaemia. Lancet 2 439-441
417. HL Muller, M Klinkhammer-Schalke, B Seelbach-Gobel, et al. (1996) Gonadal function of young adults after therapy of malignancies during childhood or adolescence. Eur J Pediatr 155 763-769
418. EJ Chow, DL Friedman, Y Yasui, et al. (2008) Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 50 854-858
419. DM Green, B Hall and MA Zevon (1989) Pregnancy outcome after treatment for acute lymphoblastic leukemia during childhood or adolescence. Cancer 64 2335-2339
420. LB Kenney, HS Nicholson, C Brasseux, et al. (1996) Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia. A Childrens Cancer Group/National Institutes of Health Report. Cancer 78 169-176
421. DL Hoover, LE Smith, SJ Turner, et al. (1988) Ophthalmic evaluation of survivors of acute lymphoblastic leukemia. Ophthalmology 95 151-155
422. L Loning, M Zimmermann, A Reiter, et al. (2000) Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 95 2770-2775
423. S Bhatia, HN Sather, OB Pabustan, et al. (2002) Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 99 4257-4264
424. N Hijiya, MM Hudson, S Lensing, et al. (2007) Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 297 1207-1215
425. M Maule, G Scelo, G Pastore, et al. (2007) Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. J Natl Cancer Inst 99 790-800
426. VM Kimball Dalton, RD Gelber, F Li, et al. (1998) Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol 16 2848-2853
427. CH Pui, FG Behm, SC Raimondi, et al. (1989) Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321 136-142
428. NJ Winick, RW McKenna, JJ Shuster, et al. (1993) Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11 209-217
429. MA Tucker, AT Meadows, JD Boice Jr, et al. (1987) Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 78 459-464
430. SG Kreissman, RD Gelber, HJ Cohen, et al. (1992) Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer 70 2208-2213
431. AW Walter, ML Hancock, CH Pui, et al. (1998) Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol 16 3761-3767
432. AL Sonis, N Tarbell, RW Valachovic, et al. (1990) Dentofacial development in long-term survivors of acute lymphoblastic leukemia. A comparison of three treatment modalities. Cancer 66 2645-2652
433. M Nesbit, W Krivit, R Heyn, et al. (1976) Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems. Cancer 37 1048-1057
434. AC Farrow, GR Buchanan, RJ Zwiener, et al. (1997) Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 15 1560-1566
435. EH Broxson, M Dole, R Wong, et al. (2005) Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. Pediatr Blood Cancer 44 226-231
436. G Henze, R Fengler, R Hartmann, et al. (1991) Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 78 1166-1172
437. K Wheeler, S Richards, C Bailey and J Chessells (1998) Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol 101 94-103
438. PS Gaynon, RP Qu, RJ Chappell, et al. (1998) Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse—the Children's Cancer Group Experience. Cancer 82 1387-1395
439. A Roy, A Cargill, S Love, et al. (2005) Outcome after first relapse in childhood acute lymphoblastic leukaemia—lessons from the United Kingdom R2 trial. Br J Haematol 130 67-75
440. HG Einsiedel, A von Stackelberg, R Hartmann, et al. (2005) Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 23 7942-7950
441. GK Rivera, Y Zhou, ML Hancock, et al. (2005) Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 103 368-376
442. M Eapen, E Raetz, MJ Zhang, et al. (2006) Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 107 4961-4967
443. F Giona, AM Testi, R Rondelli, et al. (1997) ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse. Br J Haematol 99 671-677
444. C Buhrer, R Hartmann, R Fengler, et al. (1996) Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Munster Relapse Study Group. J Clin Oncol 14 2812-2817
445. C Buhrer, R Hartmann, R Fengler, et al. (1993) Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 21 470-476
446. PD Sadowitz, SD Smith, J Shuster, et al. (1993) Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 81 602-609
447. TC Abshire, BH Pollock, AL Billett, et al. (2000) Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96 1709-1715
448. A Matsuzaki, Y Nagatoshi, H Inada, et al. (2005) Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation—a report from the Kyushu-Yamaguchi Children's Cancer Study Group. Pediatr Blood Cancer 45 111-120
449. N Hijiya, A Gajjar, Z Zhang, et al. (2004) Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse. Leukemia 18 1581-1586
450. C Eckert, A Biondi, K Seeger, et al. (2001) Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358 1239-1241
451. E Coustan-Smith, A Gajjar, N Hijiya, et al. (2004) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 18 499-504
452. AJ Barrett, MM Horowitz, BH Pollock, et al. (1994) Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 331 1253-1258
453. C Uderzo, MG Valsecchi, A Bacigalupo, et al. (1995) Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 13 352-358
454. R Dopfer, G Henze, C Bender-Gotze, et al. (1991) Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood 78 2780-2784
455. DJ Weisdorf, WG Woods, ME Nesbit Jr, et al. (1994) Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome. Br J Haematol 86 62-69
456. A Torres, MA Alvarez, J Sanchez, et al. (1999) Allogeneic bone marrow transplantation vs chemotherapy for the treatment of childhood acute lymphoblastic leukaemia in second complete remission (revisited 10 years on). Bone Marrow Transplant 23 1257-1260
457. JA Brochstein, NA Kernan, S Groshen, et al. (1987) Allogeneic bone marrow transplantation after hyperfractionated total- body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 317 1618-1624
458. SM Davies, NK Ramsay, JP Klein, et al. (2000) Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 18 340-347
459. SK Parsons, SM Castellino, LE Lehmann, et al. (1996) Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children. Bone Marrow Transplant 17 763-768
460. CJ Knechtli, NJ Goulden, JP Hancock, et al. (1998) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 92 4072-4079
461. P Bader, J Hancock, H Kreyenberg, et al. (2002) Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 16 1668-1672
462. L Sramkova, K Muzikova, E Fronkova, et al. (2007) Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 48 93-100
463. SM Davies, JE Wagner, XO Shu, et al. (1997) Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 15 557-565
464. N Bunin, M Carston, D Wall, et al. (2002) Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 99 3151-3157
465. F Locatelli, M Zecca, C Messina, et al. (2002) Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 16 2228-2237
466. AE Woolfrey, C Anasetti, B Storer, et al. (2002) Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 99 2002-2008
467. UM Saarinen-Pihkala, G Gustafsson, O Ringden, et al. (2001) No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 19 3406-3414
468. DA Jacobsohn, B Hewlett, M Ranalli, et al. (2004) Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia. Bone Marrow Transplant 34 901-907
469. A Borgmann, A von Stackelberg, R Hartmann, et al. (2003) Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 101 3835-3839
470. A Busca, C Anasetti, G Anderson, et al. (1994) Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 83 3077-3084
471. SE Sallan, CM Niemeyer, AL Billett, et al. (1989) Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol 7 1594-1601
472. AL Billett, E Kornmehl, NJ Tarbell, et al. (1993) Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood 81 1651-1657
473. MS Maldonado, C Diaz-Heredia, I Badell, et al. (1998) Autologous bone marrow transplantation with monoclonal antibody purged marrow for children with acute lymphoblastic leukemia in second remission. Spanish Working Party for BMT in Children. Bone Marrow Transplant 22 1043-1047
474. A Borgmann, H Schmid, R Hartmann, et al. (1995) Autologous bone-marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. The Berlin-Frankfurt-Munster Study Group. Lancet 346 873-876
475. N Hagedorn, C Acquaviva, E Fronkova, et al. (2007) Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of “isolated” and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood 110 4022-4029
476. SL George, JJ Ochs, AM Mauer, et al. (1985) The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. J Clin Oncol 3 776-781
477. H Behrendt, EF van Leeuwen, C Schuwirth, et al. (1989) The significance of an isolated central nervous system relapse, occurring as first relapse in children with acute lymphoblastic leukemia. Cancer 63 2066-2072
478. RC Ribeiro, GK Rivera, M Hudson, et al. (1995) An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 13 333-338
479. AK Ritchey, BH Pollock, SJ Lauer, et al. (1999) Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study. J Clin Oncol 17 3745-3752
480. JC Barredo, M Devidas, SJ Lauer, et al. (2006) Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol 24 3142-3149
481. A Borgmann, R Hartmann, H Schmid, et al. (1995) Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group. Bone Marrow Transplant 15 515-521
482. M Eapen, MJ Zhang, M Devidas, et al. (2008) Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Leukemia 22 281-286
483. C Uderzo, M Grazia Zurlo, L Adamoli, et al. (1990) Treatment of isolated testicular relapse in childhood acute lymphoblastic leukemia: an Italian multicenter study. Associazione Italiana Ematologia ed Oncologia Pediatrica. J Clin Oncol 8 672-677
484. MM Wofford, SD Smith, JJ Shuster, et al. (1992) Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 10 624-630
485. JZ Finklestein, DR Miller, J Feusner, et al. (1994) Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia. A report from the Childrens Cancer Group. Cancer 73 219-223
486. P Novakovic, SJ Kellie and D Taylor (1989) Childhood leukaemia: relapse in the anterior segment of the eye. Br J Ophthalmol 73 354-359
487. DC Heaton and GB Duff (1989) Ovarian relapse in a young woman with acute lymphoblastic leukaemia. Am J Hematol 30 42-43
488. EJ Yeoh, ME Ross, SA Shurtleff, et al. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1 133-143
489. AA Ferrando, DS Neuberg, J Staunton, et al. (2002) Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1 75-87
490. S Jeha, PS Gaynon, BI Razzouk, et al. (2006) Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24 1917-1923
491. V Del Gaizo Moore, KD Schlis, SE Sallan, et al. (2008) BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111 2300-2309
492. G Wei, D Twomey, J Lamb, et al. (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10 331-342
493. JF Dijoseph, MM Dougher, DC Armellino, et al. (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21 2240-2245
494. CH Pui, C Cheng, W Leung, et al. (2003) Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 349 640-649
495. R Mody, S Li, DC Dover, et al. (2008) Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood 111 5515-5523